Understanding the mechanisms of senile osteoporosis: New facts for a major geriatric syndrome

Journal of the American Geriatrics Society

Volumn 56, Issue 5, 2008, Pages 935-941

  Duque, Gustavo ^a   Troen, Bruce R ^b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Adipogenesis; Bone formation and resorption; Osteoblast; Osteoclast; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTRADIOL; IBANDRONIC ACID; PARATHYROID HORMONE; RESVERATROL; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ADIPOGENESIS; AGED; AGING; BONE DENSITY; CLIMACTERIUM; DRUG COST; DRUG MECHANISM; FRACTURE; HUMAN; LOW DRUG DOSE; OSSIFICATION; OSTEOLYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SENILE OSTEOPOROSIS; SYNDROME;

ADIPOCYTES; AGE FACTORS; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE MARROW; BONE REMODELING; BONE RESORPTION; CATHEPSINS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; SEX FACTORS; VITAMIN D DEFICIENCY;

EID: 43249101328     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2008.01764.x     Document Type: Review

References (85)

1. Raisz LG, Rodan GA. Pathogenesis of osteoporosis. Endocrinol Metab Clin North Am 2003 32 : 15 24.
2. Lin JT, Lane JM. Rehabilitation of the older adult with an osteoporosis-related fracture. Clin Geriatr Med 2006 22 : 435 447, x.
3. Brown LB, Streeten EA, Shapiro JR et al. Genetic and environmental influences on bone mineral density in pre- and post-menopausal women. Osteoporos Int 2005 16 : 1849 1856.
4. Tenenhouse A, Joseph L, Kreiger N et al. Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: The Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2000 11 : 897 904.
5. Colon-Emeric CS, Saag KG. Osteoporotic fractures in older adults. Best Pract Res Clin Rheumatol 2006 20 : 695 706.
6. Dempster DW. Bone microarchitecture and strength. Osteoporos Int 2003 14 : S54 S56.
7. Kim CH, Takai E, Zhou H et al. Trabecular bone response to mechanical and parathyroid hormone stimulation: The role of mechanical microenvironment. J Bone Miner Res 2003 18 : 2116 2125.
8. Raisz LG. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 2005 115 : 3318 3325.
9. Chan GK, Duque G. Age-related bone loss: Old bone, new facts. Gerontology 2002 48 : 62 71.
10. Rauch F, Travers R, Glorieux FH. Intracortical remodeling during human bone development - a histomorphometric study. Bone 2007 40 : 274 280.
11. Troen BR. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 2003 38 : 605 614.
12. Troen BR. The regulation of cathepsin K gene expression. Ann N Y Acad Sci 2006 1068 : 165 172.
13. Ellies DL, Krumlauf R. Bone formation: The nuclear matrix reloaded. Cell 2006 125 : 840 842.
14. Roodman GD. Regulation of osteoclast differentiation. Ann N Y Acad Sci 2006 1068 : 100 109.
15. Yeung RS. The osteoprotegerin/osteoprotegerin ligand family: Role in inflammation and bone loss. J Rheumatol 2004 31 : 844 846.
16. Mundy GR, Elefteriou F. Boning up on ephrin signaling. Cell 2006 126 : 441 443.
17. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000 108 : 153 164.
18. Garn SM, Rohman CG, Nolan P. The developmental nature of bone changes during aging. In : Birren JE, ed. Relations of Development and Aging. Springfield, IL : Charles C Thomas, 1966, pp 41 61.
19. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res 2002 57 : 385 409.
20. Lips P. Vitamin D status and nutrition in Europe and Asia. J Steroid Biochem Mol Biol 2007 103 : 620 625.
21. Kira M, Kobayashi T, Yoshikawa K. Vitamin D and the skin. J Dermatol 2003 30 : 429 437.
22. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001 22 : 477 501.
23. Docheva D, Popov C, Mutschler W et al. Human mesenchymal stem cells in contact with their environment: Surface characteristics and the integrin system. J Cell Mol Med 2007 11 : 21 38.
24. Gimble JM, Zvonic S, Floyd ZE et al. Playing with bone and fat. J Cell Biochem 2006 98 : 251 266.
25. de Boer J, Andressoo JO, de Wit J et al. Premature aging in mice deficient in DNA repair and transcription. Science 2002 296 : 1276 1279.
26. Mitsui A, Hamuro J, Nakamura H et al. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid Redox Signal 2002 4 : 693 696.
27. Yudoh K, Nishioka K. Telomerized presenescent osteoblasts prevent bone mass loss in vivo. Gene Ther 2004 11 : 909 915.
28. De Sandre-Giovannoli A, Bernard R, Cau P et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003 300 : 2055.
29. de Paula Rodrigues GH, das Eiras Tamega I, Duque G et al. Severe bone changes in a case of Hutchinson-Gilford syndrome. Ann Genet 2002 45 : 151 155.
30. Bergo MO, Gavino B, Ross J et al. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin a processing defect. Proc Natl Acad Sci U S A 2002 99 : 13049 13054.
31. Duque G, Rivas D. Age-related changes in lamin A/C expression in the osteoarticular system: Laminopathies as a potential new aging mechanism. Mech Ageing Dev 2006 127 : 378 383.
32. Pendas AM, Zhou Z, Cadinanos J et al. Defective prelamin a processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet 2002 31 : 94 99.
33. Hutchison CJ, Worman HJ. A-type lamins: Guardians of the soma? Nat Cell Biol 2004 6 : 1062 1067.
34. Rosen CJ, Bouxsein ML. Mechanisms of disease: Is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006 2 : 35 43.
35. Perrien DS, Akel NS, Dupont-Versteegden EE et al. Aging alters the skeletal response to disuse in the rat. Am J Physiol Regul Integr Comp Physiol 2007 292 : R988 R996.
36. McCauley LK, Tozum TF, Kozloff KM et al. Transgenic models of metabolic bone disease: Impact of estrogen receptor deficiency on skeletal metabolism. Connect Tissue Res 2003 44 : S250 S263.
37. Maurin AC, Chavassieux PM, Frappart L et al. Influence of mature adipocytes on osteoblast proliferation in human primary cocultures. Bone 2000 26 : 485 489.
38. Musacchio E, Priante G, Budakovic A et al. Effects of unsaturated free fatty acids on adhesion and on gene expression of extracellular matrix macromolecules in human osteoblast-like cell cultures. Connect Tissue Res 2007 48 : 34 38.
39. Duque G. Will reducing adopogenesis in bone increase bone mass?: PPARgamma2 as a key target in the treatment of age-related bone loss. Drug News Perspect 2003 16 : 341 346.
40. Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006 91 : 3349 3354.
41. Hampton T. Diabetes drugs tied to fractures in women. JAMA 2007 297 : 1645.
42. Botolin S, McCabe LR. Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol 2006 209 : 967 976.
43. Duque G. As a matter of fat: New perspectives on the understanding of age-related bone loss. BoneKEy-Osteovision 2007 4 : 129 140.
44. Tromp AM, Bravenboer N, Tanck E et al. Additional weight bearing during exercise and estrogen in the rat: The effect on bone mass, turnover, and structure. Calcif Tissue Int 2006 79 : 404 415.
45. Szulc P, Beck TJ, Marchand F et al. Low skeletal muscle mass is associated with poor structural parameters of bone and impaired balance in elderly men - the MINOS study. J Bone Miner Res 2005 20 : 721 729.
46. Rubin J, Rubin C, Jacobs CR. Molecular pathways mediating mechanical signaling in bone. Gene 2006 367 : 1 16.
47. Karinkanta S, Heinonen A, Sievanen H et al. A multi-component exercise regimen to prevent functional decline and bone fragility in home-dwelling elderly women: Randomized, controlled trial. Osteoporos Int 2007 18 : 453 462.
48. Uusi-Rasi K, Kannus P, Cheng S et al. Effect of alendronate and exercise on bone and physical performance of postmenopausal women: A randomized controlled trial. Bone 2003 33 : 132 143.
49. Verschueren SM, Roelants M, Delecluse C et al. Effect of 6-month whole body vibration training on hip density, muscle strength, and postural control in postmenopausal women: A randomized controlled pilot study. J Bone Miner Res 2004 19 : 352 359.
50. Gusi N, Raimundo A, Leal A. Low-frequency vibratory exercise reduces the risk of bone fracture more than walking: A randomized controlled trial. BMC Musculoskelet Disord 2006 7 : 92.
51. Bischoff-Ferrari HA, Willett WC, Wong JB et al. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA 2005 293 : 2257 2264.
52. Gloth FM. Vitamin D. In : Rosen CJ, Glowacki J, Bilezikian JP, eds. The Aging Skeleton. San Diego, CA : Academic Press, 1999.
53. Duque G, Macoritto M, Dion N et al. 1,25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6). Am J Physiol Endocrinol Metab 2005 288 : E723 E730.
54. Duque G, El Abdaimi K, Henderson JE et al. Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Fas-related pathways. Bone 2004 35 : 57 64.
55. Duque G, Macoritto M, Kremer R. Vitamin D treatment of senescence accelerated mice (SAM-P/6) induces several regulators of stromal cell plasticity. Biogerontology 2004 5 : 421 429.
56. Zhang Y, Lai WP, Wu CF et al. Ovariectomy worsens secondary hyperparathyroidism in mature rats during low-Ca diet. Am J Physiol Endocrinol Metab 2007 292 : E723 E731.
57. Mann V, Huber C, Kogianni G et al. The antioxidant effect of estrogen and selective estrogen receptor modulators in the inhibition of osteocyte apoptosis in vitro. Bone 2007 40 : 674 684.
58. Prestwood KM, Kenny AM, Kleppinger A et al. Ultralow-dose micronized 17 beta-estradiol and bone density and bone metabolism in older women: A randomized controlled trial. JAMA 2003 290 : 1042 1048.
59. Burger HG. Hormone therapy in the WHI era. Aust N Z J Obstet Gynaecol 2006 46 (2) : 84 91.
60. Adler RA. Epidemiology and pathophysiology of osteoporosis in men. Curr Osteoporos Rep 2006 4 : 110 115.
61. Leifke E, Korner HC, Link TM et al. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrin/Eur Federation Endocrine Soc 1998 138 : 51 58.
62. Behre HM, Kliesch S, Leifke E et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997 82 (8) : 2386 2390.
63. Steidle CP. New advances in the treatment of hypogonadism in the aging male. Rev Urol 2003 5 (Suppl 1) : S34 S40.
64. Vanderschueren D, Vandenput L, Boonen S et al. Androgens and bone. Endocr Rev 2004 25 (3) : 389 425.
65. Mulder JE, Kolatkar NS, LeBoff MS. Drug insight: Existing and emerging therapies for osteoporosis. Nat Clin Pract Endocrinol Metab 2006 2 (12) : 670 680.
66. Russell RG. Bisphosphonates: From bench to bedside. Ann N Y Acad Sci 2006 1068 : 367 401.
67. Duque G, Rivas D. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 2007 22 : 1603 1611.
68. Boonen S. Treatment of senile osteoporosis: Present and future. In : Duque G, Kiel DP, eds. Osteoporosis in Older Persons: Pathophysiology and Therapeutic Approach. New York, NY : Springer, 2007.
69. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007 356 : 1809 1822.
70. Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007 357 : 1799 1809.
71. Manuele S, Sorbello L, Puglisi N et al. The teriparatide in the treatment of severe senile osteoporosis. Arch Gerontol Geriatr 2007 44 : S249 S258.
72. Hamann KL, Lane NE. Parathyroid hormone update. Rheum Dis Clin North Am 2006 32 : 703 719.
73. Chen P, Miller PD, Delmas PD et al. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006 21 : 1785 1790.
74. Boonen S, Marin F, Mellstrom D et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: Bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006 54 : 782 789.
75. O'Donnell S, Cranney A, Wells GA et al. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006: CD005326.
76. Seeman E, Vellas B, Benhamou C et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006 21 : 1113 1120.
77. Backesjo CM, Li Y, Lindgren U et al. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res 2006 21 : 993 1002.
78. David V, Martin A, Lafage-Proust MH et al. Mechanical loading down-regulates peroxisome proliferator-activated receptor gamma in bone marrow stromal cells and favors osteoblastogenesis at the expense of adipogenesis. Endocrinology 2007 148 : 2553 2562.
79. Chapurlat RD, Delmas PD. Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2006 2 : 211 219 quiz following 238.
80. Zaidi M, Blair HC, Moonga BS et al. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 2003 18 : 599 609.
81. Selander KS, Harkonen PL, Valve E et al. Calcitonin promotes osteoclast survival in vitro. Mol Cell Endocrinol 1996 122 : 119 129.
82. Rickard DJ, Wang FL, Rodriguez-Rojas AM et al. Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 2006 39 : 1361 1372.
83. Michael H, Harkonen PL, Kangas L et al. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol 2007 151 : 384 395.
84. Marie PJ. Strontium ranelate: New insights into its dual mode of action. Bone 2007 40 : S5 S8.
85. Suda T, Ueno Y, Fujii K et al. Vitamin D and bone. J Cell Biochem 2003 88 : 259 266.